TENAX THERAPEUTICS INC (TENX) — insider trading
Health Care · NASDAQ
TENAX THERAPEUTICS INC (TENX) has 27 reported SEC Form 4 insider transactions in our data, including 13 open-market purchases among the most recent 27 (latest 2026-09-16).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-16 | Doogan Declan | Director | Open-market purchase | 53,000 | $1.92 | $101.8K | Form 4 |
| 2026-09-15 | Giordano Christopher Thomas | Director, Officer (CEO) | Open-market purchase | 4,850 | $1.82 | $8.8K | Form 4 |
| 2026-09-11 | STAAB THOMAS R II | Officer (Chief Financial Officer) | Open-market purchase | 5,675 | $1.94 | $11.0K | Form 4 |
| 2026-09-11 | Giordano Christopher Thomas | Director, Officer (CEO) | Open-market purchase | 6,000 | $1.88 | $11.3K | Form 4 |
| 2026-09-03 | ADAR1 Capital Management, LLC; Schneeberger Daniel | 10% owner | Open-market purchase | 900,000 | $1.78 | $1.60M | Form 4 |
| 2026-09-02 | ADAR1 Capital Management, LLC; Schneeberger Daniel | 10% owner | Open-market purchase | 187,704 | $1.80 | $337.6K | Form 4 |
| 2026-09-01 | ADAR1 Capital Management, LLC; Schneeberger Daniel | 10% owner | Open-market purchase | 179,058 | $1.80 | $321.6K | Form 4 |
| 2026-08-31 | ADAR1 Capital Management, LLC; Schneeberger Daniel | 10% owner | Open-market purchase | 403,571 | $1.79 | $722.6K | Form 4 |
| 2026-08-24 | ADAR1 Capital Management, LLC; Schneeberger Daniel | 10% owner | Open-market purchase | 107,374 | $1.75 | $188.4K | Form 4 |
| 2026-08-21 | ADAR1 Capital Management, LLC; Schneeberger Daniel | 10% owner | Open-market purchase | 716,369 | $1.77 | $1.27M | Form 4 |
| 2026-08-20 | ADAR1 Capital Management, LLC; Schneeberger Daniel | 10% owner | Open-market purchase | 202,124 | $1.78 | $359.5K | Form 4 |
| 2026-07-13 | Giordano Christopher Thomas | Director, Officer (CEO) | Option exercise / conversion (derivative) | 8,500 | — | $0 | Form 4 |
| 2026-07-13 | Giordano Christopher Thomas | Director, Officer (CEO) | Option exercise / conversion (derivative) | 219 | — | $0 | Form 4 |
| 2026-07-13 | Giordano Christopher Thomas | Director, Officer (CEO) | Option exercise / conversion | 8,500 | $5.94 | $50.5K | Form 4 |
| 2026-07-13 | Giordano Christopher Thomas | Director, Officer (CEO) | Option exercise / conversion | 219 | $3.55 | $777 | Form 4 |
| 2026-05-11 | STAAB THOMAS R II | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 450,000 | — | $0 | Form 4 |
| 2026-05-11 | STAAB THOMAS R II | Officer (Chief Financial Officer) | Grant / award / vesting | 10,000 | — | $0 | Form 4 |
| 2026-01-30 | MCGAULEY THOMAS | Officer (Interim CFO) | Option exercise / conversion (derivative) | 50,000 | — | $0 | Form 4 |
| 2026-01-09 | Hunter Robyn | Director | Grant / award / vesting (derivative) | 30,000 | — | $0 | Form 4 |
| 2026-01-09 | Doogan Declan | Director | Grant / award / vesting (derivative) | 30,000 | — | $0 | Form 4 |
| 2026-01-09 | Almenoff June Sherie | Director | Grant / award / vesting (derivative) | 30,000 | — | $0 | Form 4 |
| 2026-01-09 | PROEHL GERALD T | Director | Grant / award / vesting (derivative) | 3,000 | — | $0 | Form 4 |
| 2026-01-09 | Rich Stuart | Director, Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 250,000 | — | $0 | Form 4 |
| 2026-01-09 | Giordano Christopher Thomas | Director, Officer (CEO) | Grant / award / vesting (derivative) | 450,000 | — | $0 | Form 4 |
| 2026-01-09 | Davidson Michael H. | Director | Grant / award / vesting (derivative) | 30,000 | — | $0 | Form 4 |
| 2025-12-09 | Rich Stuart | Director, Officer (Chief Medical Officer) | Open-market purchase | 2,500 | $10.22 | $25.5K | Form 4 |
| 2025-12-08 | Rich Stuart | Director, Officer (Chief Medical Officer) | Open-market purchase | 2,500 | $10.10 | $25.3K | Form 4 |
Ask the chat about TENX's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: TENAX THERAPEUTICS INC (TENX).
Last updated 2026-09-16 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.